

NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers V.1.2020 –Annual 10-01-19

Guideline Page and Request	Panel Discussion/References	Vote			
		YES	NO	ABSTAIN	ABSENT
<p>ESOPH-1, ESOPH-19, ESOPH-B (4 of 6) External request Submission from Promega Corporation (09/23/19) requesting the panel to equally emphasize any assay for the detection of microsatellite instability (MSI) that has been validated in esophageal cancers be given equal weight and be recommended as a parallel technology with mismatch repair deficiency (MMR) protein expression analysis by immunohistochemistry (IHC) for Esophageal cancer patients.</p>	<p>Based on the review of the data and discussion, the panel consensus was to include to emphasize analysis by IHC in the following pages of the guidelines:</p> <p><u>ESOPH-1</u></p> <ul style="list-style-type: none"> Workup: MSI-H/dMMR <i>MSI by PCR/MMR by IHC</i>, and PD-L1 testing if metastatic disease is documented/suspected. <p><u>ESOPH-10</u></p> <ul style="list-style-type: none"> Perform <i>MSI by PCR/MMR by IHC</i> and PD-L1 testing... <p><u>ESOPH-19</u></p> <ul style="list-style-type: none"> Perform <i>MSI by PCR/MMR by IHC</i>, PD-L1 and HER2 testing... <p><u>ESOPH-B (4 of 6)</u></p> <ul style="list-style-type: none"> “MMR or Testing for MSI by polymerase chain reaction (PCR) or MMR by IHC testing should be considered on locally advanced...” IHC for MMR and PCR for MSI are different assays measuring the same biological effect. PCR for MSI and IHC for MMR proteins measures different biological effects caused by dMMR function. 	23	0	0	5
<p>ESOPH-1 External Request Submission from CDx Diagnostics, Inc (09/06/19) to consider in all relevant NCCN Esophageal Guideline sections that outline diagnostic work-ups to detect Barrett’s esophagus and associated dysplasia in patients undergoing endoscopic screening or surveillance, request that Wide Area Transepithelial Sampling with Computer-Assisted Three Dimensional Tissue Analysis (WATS3D) be included as an adjunct to the Seattle random forceps biopsy protocol.</p>	<p>Based on a review of the data and discussion, the panel consensus did not support the inclusion of the WATS3D for use with patients undergoing screening or surveillance endoscopy for suspected or known Barrett’s esophagus.</p>	0	23	0	5